Literature DB >> 31327837

An Immunocompetent Case of Capnocytophaga canimorsus Infection Complicated by Secondary Thrombotic Microangiopathy and Disseminated Intravascular Coagulation.

Naoki Tani1, Keiji Nakamura1, Kosuke Sumida1, Michio Suzuki2, Koichi Imaoka2, Nobuyuki Shimono3.   

Abstract

A 62-year-old woman with no previous history developed a Capnocytophaga canimorsus infection followed by thrombotic microangiopathy (TMA) and disseminated intravascular coagulation (DIC). She was treated with antibiotics and plasma exchange (PE) and recovered. C. canimorsus sepsis sometimes causes not only DIC but also TMA. The mortality of TMA is extremely high, so we should not hesitate to perform PE when a patient shows TMA symptoms.

Entities:  

Keywords:  Capnocytophaga canimorsus; disseminated intravascular coagulation; emerging infection; sepsis; thrombotic microangiopathy

Mesh:

Substances:

Year:  2019        PMID: 31327837      PMCID: PMC6928499          DOI: 10.2169/internalmedicine.3110-19

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


Introduction

Capnocytophaga spp. is part of the normal oral flora of dogs, cats, and humans, and there are nine species. Most serious and fatal cases are due to Capnocytophaga canimorsus. C. canimorsus infection is rare considering the frequency of animal bites and scratches, but patients can develop severe sepsis, and the mortality rate is over 30% (1). Furthermore, C. canimorsus sepsis can develop into thrombotic microangiopathy (TMA), which requires advanced treatment, such as hemodialysis or plasma exchange (PE). We herein report an immunocompetent case of C. canimorsus sepsis complicated with TMA. The patient recovered because of adequate antibiotic therapy and prompt performance of PE.

Case Report

A 62-year-old woman with no previous history consulted her previous doctor with a fever, stomachache, and diarrhea. She had been bitten by her own dog two days before. She developed a fever over 38℃ and had low blood pressure. She was transferred to our hospital with suspicion of septic shock. On admission, an assessment of her vital signs revealed mild consciousness disorder of Glasgow Coma Scale E3V5M6, blood pressure of 93/53 mmHg, heart rate of 90 beats per minute, respiratory rate of 20 breaths per minute, and oxygen saturation of 97% under room air. A physical examination revealed left flank pain and a bite scar in her left hand without signs of infection. There was no lymphadenopathy, and her respiratory and heart sounds were normal. Her laboratory data during admission are shown in Fig. 1. On admission, the laboratory data showed signs of disseminated intravascular coagulation [DIC; platelet 29,000 /μL, D-dimer 39.0 μg/mL, prothrombin time-international normalized ratio (PT-INR) 1.46, fibrinogen 165 mg/dL], mild elevation of bilirubin (1.7 mg/dL) and LDH (396 IU/L), and elevation of procalcitonin (13.80 ng/mL). Chest X-ray showed pulmonary congestion and bilateral pleural effusion. Contrast-enhanced computed tomography (CT) revealed complete non-enhancement of the spleen, suggesting splenic infarction (Fig. 2).
Figure 1.

Clinical course, treatment, and laboratory data. We applied plasma exchange for thrombotic microangiopathy on days 5-7 and 9-11, and most data improved, such as the platelet count, serum creatinine level, and lactate dehydrogenase level.

Figure 2.

CT revealed hepatomegaly, non-enhancement of the spleen, and lower gastrointestinal tract edema.

Clinical course, treatment, and laboratory data. We applied plasma exchange for thrombotic microangiopathy on days 5-7 and 9-11, and most data improved, such as the platelet count, serum creatinine level, and lactate dehydrogenase level. CT revealed hepatomegaly, non-enhancement of the spleen, and lower gastrointestinal tract edema. We diagnosed her with severe sepsis complicated with DIC and started antibiotic therapy with piperacillin/tazobactam (days 1-3: 4.5 g ×3, days 4-9: 2.25 g ×4), administered thrombomodulin alfa (days 2-5: 12,800 U), and performed platelet transfusion because of bleeding from her mouth (days 2 and 4: 10 U). On day 3, slim Gram-negative rods were isolated from blood culture. Considering her episode of dog bite, we suspected this organism to be Capnocytophaga sp. Despite treatment for DIC and improvement of her coagulation, schistocytes appeared, and haptoglobin (determined by a nephelometry test) was undetectable on day 5. We diagnosed her with TMA because of the presence of four of the five main signs: a fever, thrombocytopenia, schistocyte, and renal involvement (2). We started PE to treat TMA immediately after the diagnosis. The platelet count recovered, and the symptoms of hemolytic anemia disappeared after PE. PE was performed six times in total. A disintegrin-like and metalloprotease with thrombospondin type 1 motifs 13 (ADAMTS13) activity was 77.2%, and the inhibitor (both determined by an enzyme-linked immunosorbent assay) was negative (both examined on day 5). A stool culture examined on admission for Enterohemorrhagic Escherichia coli, which produces Shiga toxin, was negative. The species was identified as Capnocytophaga sp. on day 11, and we switched the antibiotics from piperacillin/tazobactam to ampicillin and amoxicillin on day 21 according to the susceptibility results. Schistocytes disappeared on day 27. The pathogen was finally identified as C. canimorsus by a genetic examination (polymerase chain reaction of the 16S rRNA gene and gyrB-specific gene) at the National Institute of Infectious Diseases, Japan.

Discussion

Capnocytophaga spp., which is characterized by facultatively anaerobic, thin and fusiform Gram-negative rods, is part of the normal oral flora of dogs, cats, and humans. This organism includes nine species (3), of which six exist naturally in the human mouth, while the other three exist in animals' mouths and infect humans through bites or scratches. C. canimorsus, which inhabits the oral cavity of dogs and cats, has the highest virulence of the three species and causes not only DIC but also TMA. First, we diagnosed our case as one of C. canimorsus sepsis complicated by DIC. DIC mimics TMA-like symptoms, making it sometimes difficult to determine whether symptoms can be attributed to DIC, TMA, or both. In our case, despite treatment for DIC, schistocytes suddenly appeared, and thrombocytopenia and hemolytic anemia worsened despite improvements in the DIC markers, such as PT-INR, ATIII, and fibrinogen degradation product (FDP) (Fig. 1). We therefore diagnosed the patient with DIC complicated with TMA on day 5. TMA presents with typical symptoms, such as hemolytic anemia, the appearance of schistocytes, and organ dysfunction caused by thrombosis. In addition to hemolysis, haptoglobin is consumed to bind free hemoglobin. From a pathological perspective, these symptoms are triggered by endothelium and vessel wall damage, which is caused by arteriolar and capillary thrombosis (4). TMA includes thrombotic thrombocytopenic purpura (TTP), hemolytic uremic syndrome (HUS), atypical HUS (aHUS) caused by error of complement control factor, and secondary TMA after infection, collagen diseases, malignancy, etc. We initially suspected this to be a case of TTP, but we dismissed this notion because the ADAMTS13 activity was normal (77.2%) and the inhibitor was negative. Shiga-toxin, which would trigger HUS, wasn't detected. To diagnose aHUS, we must rule out the possibility of secondary TMA first, so we ultimately diagnosed her with secondary TMA after infection (5). We searched the PubMed, for English-language reports of cases of C. canimorsus infection complicated by TMA and identified 10 cases, summarized in Table (1,6-13). The ADAMTS13 activity was measured in only two previous case reports (6,7) and was normal, as in the present case. This phenomenon has been described in some pathogenic organisms, such as bacteria, angioinvasive fungi, viruses, and rickettsiae, that cause endothelial injury (14). The mechanisms of TMA in Capnocytophaga infection cases with normal ADAMTS13 activity are unclear; however, it is said that C. canimorsus infection presents with a strong inflammatory response, leading to microvascular injury of the endothelium (15), which may induce the TMA onset. The mechanisms underlying the low ADAMTS13 activity are also unclear, but two hypotheses have been proposed: 1) excessive activation or damage of the endothelium (7) or 2) activation of granulocyte elastase and other proteases in DIC patients with sepsis (16). Our patient differed from other cases in that TMA developed secondary to DIC, whereas all previous cases were complicated with TMA from the outset. Platelet transfusions to patients suspected of having TTP are supposed to be contraindicated due to the risk of precipitating further thrombotic events (17), so we cannot exclude the possibility that platelet transfusion might have triggered TMA in our case.
Table.

A Review of Sepsis Case Reports of Capnocytophaga canimorsus Complicated with Thrombotic Microangiopathy.

referenceyearage/sexexposurerisk factorADAMTS13/inhibitorantibioticstreatmentoutcome
8199172/MaleCat scratchNAnot measuredGMSteroidsSurvive
MFIPCPE
Crystalline PC
8199149/Malenonesplenectomynot measuredIPMnoneSurvive
9199653/FemaleDog lickheavy smokernot measuredPCGSteroidsSurvive
NTLPE
HF
Ventilation
10199950/MaleDog biteNAnot measuredAMPC/CVAPESurvive
11199947/MaleOwned dogalcoholismnot measuredAMPC/CVAPESurvive
OFLXHDF
12200166/MaleDog biteNAnot measuredCXMPlasmapheresisSurvive
MNZHD
AMPC/CVA
13201272/MaleDog bitenonenot measuredPIPC/TAZPESurvive
IMP
MEPM
1201356/MaleDog bitesplenectomynot measuredVCMSteroidsSurvive
PIPC/TAZPE
ABPC/SBT
6201661/MaleDog bitenone39%/ not measuredMEPMPESurvive
CLDMCRRT
ABPC/SBT
7201863/MaleOwned dogalcoholismless than 1%/ not measuredCTRXplasma infusionSurvive
our case62/FemaleDog bitenone77.2%/ negativePIPC/TAZPESurvive
ABPC
AMPC

NA: not available, PIPC/TAZ: piperacillin/tazobactam, IPM: imipenem, MEPM: meropenem, CLDM: clindamycin, ABPC: ampicillin, ABPC/SBT: ampicillin–sulbactam, PCG: benzylpenicillin, NTL: netilmicin, VCM: vancomycin, AMPC: amoxicillin, AMPC/CVA: amoxicillin/clavulanate, OFLX: ofloxacin, CTRX: ceftriaxon, CXM: cefuroxime, MNZ: metronidazole, GM: gentamicin, MFIPC: flucloxacillin, PC: penicillin, PE: plasma exchange, CRRT: continuous renal replacement therapy, HD: hemodialysis, HF: hemofiltration, HDF: hemodiafiltration

A Review of Sepsis Case Reports of Capnocytophaga canimorsus Complicated with Thrombotic Microangiopathy. NA: not available, PIPC/TAZ: piperacillin/tazobactam, IPM: imipenem, MEPM: meropenem, CLDM: clindamycin, ABPC: ampicillin, ABPC/SBT: ampicillin–sulbactam, PCG: benzylpenicillin, NTL: netilmicin, VCM: vancomycin, AMPC: amoxicillin, AMPC/CVA: amoxicillin/clavulanate, OFLX: ofloxacin, CTRX: ceftriaxon, CXM: cefuroxime, MNZ: metronidazole, GM: gentamicin, MFIPC: flucloxacillin, PC: penicillin, PE: plasma exchange, CRRT: continuous renal replacement therapy, HD: hemodialysis, HF: hemofiltration, HDF: hemodiafiltration Among the 10 previous cases (Table), the patients' age ranges from 47 to 72 years old, with a mean age of 59 years old. There were four immunocompromised patients, alcoholism and post-splenectomy. Besides a dog-bite history, three patients had only a history of dog-lick or kept a dog as a pet, and one patient had a cat-scratch history. Some Capnocytophaga strains are β-lactamase-producing (18), so we should administer a β-lactamase inhibitor (such as piperacillin/tazobactam) or a carbapenem (such as meropenem) until the sensitivity is revealed. In our case, we changed the antibiotics after confirming that this strain was susceptible to benzyl penicillin. In most cases, PE was performed to treat TMA. Once TMA occurred, the mortality was extremely high (over 90%) without PE, although it decreased to 22% with PE (2,19). We must therefore bear in mind the possibility of the emergence of TMA, not only DIC, especially in cases of C. canimorsus infection.

The authors state that they have no Conflict of Interest (COI).
  19 in total

1.  Bacteremia due to Capnocytophaga species in patients with neutropenia: high frequency of beta-lactamase-producing strains.

Authors:  S Maury; T Leblanc; P Rousselot; P Legrand; G Arlet; C Cordonnier
Journal:  Clin Infect Dis       Date:  1999-05       Impact factor: 9.079

2.  A patient with thrombotic thrombocytopenic purpura caused by Capnocytophaga canimorsus septicemia.

Authors:  R. H. J. Kok; M. J. H. M. Wolfhagen; B. M. Mooi; J. J. G. Offerman
Journal:  Clin Microbiol Infect       Date:  1999-05       Impact factor: 8.067

3.  A syndrome resembling thrombotic thrombocytopenic purpura associated with Capnocytophaga canimorsus septicemia.

Authors:  J D Scarlett; H G Williamson; P J Dadson; R Fassett; M M Peel
Journal:  Am J Med       Date:  1991-01       Impact factor: 4.965

4.  Overwhelming Capnocytophaga canimorsus infection in a patient with asplenia.

Authors:  Lokesh Shahani; Nancy Khardori
Journal:  BMJ Case Rep       Date:  2014-04-23

Review 5.  Syndromes of thrombotic microangiopathy.

Authors:  James N George; Carla M Nester
Journal:  N Engl J Med       Date:  2014-08-14       Impact factor: 91.245

6.  Systemic infections mimicking thrombotic thrombocytopenic purpura.

Authors:  Kristina K Booth; Deirdra R Terrell; Sara K Vesely; James N George
Journal:  Am J Hematol       Date:  2011-09       Impact factor: 10.047

7.  The Oklahoma Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome (TTP-HUS) Registry: a community perspective of patients with clinically diagnosed TTP-HUS.

Authors:  James N George; Sara K Vesely; Deirdra R Terrell
Journal:  Semin Hematol       Date:  2004-01       Impact factor: 3.851

8.  Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies.

Authors:  Marie Scully; Beverley J Hunt; Sylvia Benjamin; Ri Liesner; Peter Rose; Flora Peyvandi; Betty Cheung; Samuel J Machin
Journal:  Br J Haematol       Date:  2012-05-25       Impact factor: 6.998

Review 9.  How I treat thrombotic thrombocytopenic purpura and atypical haemolytic uraemic syndrome.

Authors:  Marie Scully; Tim Goodship
Journal:  Br J Haematol       Date:  2014-01-06       Impact factor: 6.998

10.  Capnocytophaga canimorsus infection presenting with complete splenic infarction and thrombotic thrombocytopenic purpura: a case report.

Authors:  Michal Brichacek; Peter Blake; Raymond Kao
Journal:  BMC Res Notes       Date:  2012-12-26
View more
  7 in total

1.  The use of eculizumab in Capnocytophaga canimorsus associated thrombotic microangiopathy: a case report.

Authors:  Magnus Holter Bjørkto; Andreas Barratt-Due; Ingvild Nordøy; Christina Dörje; Eivind Galteland; Andreas Lind; Abdulkarim Hilli; Pål Aukrust; Geir Mjøen
Journal:  BMC Infect Dis       Date:  2021-02-01       Impact factor: 3.090

2.  Bilateral acute renal cortical necrosis after a dog bite: case report.

Authors:  Alexa Hollinger; Martin Siegemund; Simon A Amacher; Kirstine K Søgaard; Coralie Nkoulou; Raoul Sutter; Maja Weisser; Sandra S Zingg; Adrian Egli
Journal:  BMC Infect Dis       Date:  2021-02-27       Impact factor: 3.090

3.  Capnocytophaga canimorsus infection led to progressively fatal septic shock in an immunocompetent patient.

Authors:  Ryuichi Nakayama; Shuichi Miyamoto; Toshihiro Tawara; Arisa Aoyagi; Takeo Oguro; Nobumichi Kobayashi; Michio Suzuki; Yoshihiro Takeyama
Journal:  Acute Med Surg       Date:  2022-02-19

4.  Exposure of Thomsen-Friedenreich Antigen on the Renal Tubules of a Patient with Capnocytophaga Infection-induced Acute Kidney Injury.

Authors:  Takahiro Uchida; Takashi Oda; Dan Inoue; Shuhei Komatsu; Tadasu Kojima; Tomohiro Tomiyasu; Noriko Yoshikawa; Muneharu Yamada
Journal:  Intern Med       Date:  2021-08-31       Impact factor: 1.282

5.  Cellulitis and transient bacteremia by Capnocytophaga canis after a cat scratch in an immunocompetent patient.

Authors:  Domingo Fernández Vecilla; Estíbaliz Ugalde Zarraga; Mikel Joseba Urrutikoechea-Gutiérrez; Francesco Renzi; José Luis Díaz de Tuesta Del Arco
Journal:  Access Microbiol       Date:  2022-05-18

6.  A case of septic arthritis caused by Capnocytophaga canimorsus in an HIV patient.

Authors:  Domingo Fernández Vecilla; Cristina Aspichueta Vivanco; Itziar Angulo López; Josu Mirena Baraia-Etxaburu Artetxe; Francesco Renzi; José Luis Díaz de Tuesta Del Arco
Journal:  Access Microbiol       Date:  2022-06-15

Review 7.  Complement in Secondary Thrombotic Microangiopathy.

Authors:  Lilian Monteiro Pereira Palma; Meera Sridharan; Sanjeev Sethi
Journal:  Kidney Int Rep       Date:  2020-10-21
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.